Partnerships are a key cornerstone to LCT’s success over the years. We are always interested in expanding our relationships that can accelerate the development of our products and research programs, and expand our global reach.

LCT has partnered with Otsuka Pharmaceutical Factory, Inc. (OPF) to form a 50/50 company Diatranz Otsuka Limited (DOL). LCT transferred DIABECELL®, its most advanced therapeutic candidate, into the DOL joint venture and Otsuka vested A$25m to fund the final phase of development of DIABECELL. This partnership will accelerate the commercialisation of DIABECELL.

LCT and OPF have also agreed to co-develop NTCELL for Parkinson’s disease. Under the agreement, OPF will fund the Phase I trial of NTCELL in Parkinson’s disease in New Zealand. If the Phase I trial is successful, OPF will invest a further A$20 million into DOL to fund further development of NTCELL.

Only indication-specific intellectual property is transferred into the joint venture, such as treatments for type 1 diabetes or Parkinson’s disease. LCT retains a perpetual exclusive licence to leverage intellectual property outside the fields of diabetes and Parkinson’s disease. LCT also retains 100% ownership of research and development know-how to leverage its NTCELL and DIABECELL assets, and 100% ownership of IMMUPEL intellectual property.

Our breakthrough encapsulation delivery technology, IMMUPEL
, is available for license. We will process your live cells in our GMP facility for your research program, enabling your therapy to be delivered without immunosuppression.

LCT also has biocertified porcine tissue available for medical use, and we are actively seeking partners interested in these biomaterials.

LCT has the world’s only internationally accredited xenodiagnostic laboratory, and is available for molecular diagnostic testing.

For additional information on any of these partnering opportunities,please contact us at